Search Results - Vanni Borghi

  • Showing 1 - 18 results of 18
Refine Results
  1. 1
    Adherence to lipid-lowering medication in people living with HIV: An outpatient clinic drug direct distribution experience

    Adherence to lipid-lowering medication in people living with HIV: An outpatient clinic drug direct distribution experience by Gianluca Cuomo, Alessandro Raimondi, Marianna Rivasi, Giovanni Guaraldi, Vanni Borghi, Cristina Mussini

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study

    Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study by Filippo Lagi, Annarita Botta, Arturo Ciccullo, Chiara Picarelli, Massimiliano Fabbiani, Simona di Giambenedetto, Vanni Borghi, Cristina Mussini, Alessandro Bartoloni, Gaetana Sterrantino

    Published 2021-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Reliable and accurate CD4+ T cell count and percent by the portable flow cytometer CyFlow MiniPOC and "CD4 Easy Count Kit-Dry", as revealed by the comparison with the gold standard dual platform technology.

    Reliable and accurate CD4+ T cell count and percent by the portable flow cytometer CyFlow MiniPOC and "CD4 Easy Count Kit-Dry", as revealed by the comparison with the gold standard... by Milena Nasi, Sara De Biasi, Elena Bianchini, Lara Gibellini, Marcello Pinti, Tiziana Scacchetti, Tommaso Trenti, Vanni Borghi, Cristina Mussini, Andrea Cossarizza

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.

    Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. by Jose M Miro, Christian Manzardo, Cristina Mussini, Margaret Johnson, Antonella d'Arminio Monforte, Andrea Antinori, M John Gill, Laura Sighinolfi, Caterina Uberti-Foppa, Vanni Borghi, Caroline Sabin, Late Presenters Investigators

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

    Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype by Pierluigi Francesco Salvo, Damiano Farinacci, Arturo Ciccullo, Vanni Borghi, Stefano Rusconi, Annalisa Saracino, William Gennari, Bianca Bruzzone, Ilaria Vicenti, Annapaola Callegaro, Antonio Di Biagio, Maurizio Zazzi, Simona Di Giambenedetto, Alberto Borghetti

    Published 2023-03-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study

    Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study by Roberta Gagliardini, Michela Baccini, Sara Modica, Francesca Montagnani, Giacomo Zanelli, Alberto Borghetti, Emanuela Dreassi, Francesca Lombardi, Monica Pecorari, Vanni Borghi, Annapaola Callegaro, Valeria Micheli, Marco Annovazzi Lodi, Barbara Rossetti, Maurizio Zazzi

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy.

    T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy. by Andrea Cossarizza, Linda Bertoncelli, Elisa Nemes, Enrico Lugli, Marcello Pinti, Milena Nasi, Sara De Biasi, Lara Gibellini, Jonas P Montagna, Marco Vecchia, Lisa Manzini, Marianna Meschiari, Vanni Borghi, Giovanni Guaraldi, Cristina Mussini

    Published 2012-01-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

    Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients by Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto

    Published 2023-05-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

    Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort by Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi, Filippo Lagi, Alessandra Latini, Gabriella d’Ettorre, Letizia Oreni, Paolo Fusco, Amedeo Capetti, Massimiliano Fabbiani, Andrea Giacomelli, Alessandro Grimaldi, Giordano Madeddu, Gaetana Sterrantino, Cristina Mussini, Simona Di Giambenedetto

    Published 2022-01-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors

    Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors by Rossana Scutari, Claudia Alteri, Ilaria Vicenti, Domenico Di Carlo, Valentina Zuccaro, Francesca Incardona, Vanni Borghi, Antonia Bezenchek, Massimo Andreoni, Andrea Antinori, Carlo Federico Perno, Antonio Cascio, Andrea De Luca, Maurizio Zazzi, Maria Mercedes Santoro

    Published 2020-03-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

    A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). by Cristina Mussini, Enrica Roncaglia, Vanni Borghi, Stefano Rusconi, Silvia Nozza, Anna Maria Cattelan, Daniela Segala, Paolo Bonfanti, Antonio Di Biagio, Enrico Barchi, Emanuele Focà, Anna Degli Antoni, Stefano Bonora, Daniela Francisci, Silvia Limonta, Andrea Antinori, Gabriella D'Ettorre, Franco Maggiolo

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice

    Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical pra... by Daniele Armenia, Federica Forbici, Ada Bertoli, Giulia Berno, Vincenzo Malagnino, Roberta Gagliardini, Vanni Borghi, William Gennari, Stefania Cicalini, Annarita Buonomini, Elisabetta Teti, Simone Lanini, Alessandra Latini, Loredana Sarmati, Cristina Mussini, Massimo Andreoni, Andrea Antinori, Carlo F. Perno, Francesca Ceccherini-Silberstein, Maria M. Santoro

    Published 2022-09-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE trial

    Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE... by Andrea Cossarizza, Alessandro Cozzi-Lepri, Marco Mattioli, Annamaria Paolini, Anita Neroni, Sara De Biasi, Domenico Lo Tartaro, Rebecca Borella, Lucia Fidanza, Lara Gibellini, Barbara Beghetto, Enrica Roncaglia, Giulia Nardini, Jovana Milic, Marianna Menozzi, Gianluca Cuomo, Margherita Digaetano, Gabriella Orlando, Vanni Borghi, Giovanni Guaraldi, Giovanni Guaraldi, Cristina Mussini, Cristina Mussini

    Published 2023-10-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study

    Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study by Cristina Mussini, Alessandro Cozzi-Lepri, Marianna Meschiari, Erica Franceschini, Giulia Burastero, Matteo Faltoni, Giacomo Franceschi, Vittorio Iadisernia, Sara Volpi, Andrea Dessilani, Licia Gozzi, Jacopo Conti, Martina Del Monte, Jovana Milic, Vanni Borghi, Roberto Tonelli, Lucio Brugioni, Elisa Romagnoli, Antonello Pietrangelo, Elena Corradini, Massimo Girardis, Stefano Busani, Andrea Cossarizza, Enrico Clini, Giovanni Guaraldi

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia

    Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia by Alessandro Cozzi-Lepri, Vanni Borghi, Salvatore Rotundo, Bianca Mariani, Anna Ferrari, Cosmo Del Borgo, Francesca Bai, Pietro Colletti, Piermauro Miraglia, Carlo Torti, Anna Maria Cattelan, Giovanni Cenderello, Marco Berruti, Carlo Tascini, Giustino Parruti, Simona Coladonato, Andrea Gori, Giulia Marchetti, Miriam Lichtner, Luigi Coppola, Chiara Sorace, Alessandra D'Abramo, Valentina Mazzotta, Giovanni Guaraldi, Erica Franceschini, Marianna Meschiari, Loredana Sarmati, Andrea Antinori, Emanuele Nicastri, Cristina Mussini

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.

    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. by Lucia Taramasso, Antonio Di Biagio, Francesca Bovis, Laura Ambra Nicolini, Andrea Antinori, Laura Milazzo, Salvatore Sollima, Guido Gubertini, Fosca Niero, Annalisa Saracino, Raffaele Bruno, Vanni Borghi, Francesca Montagnani, Annamaria Cattelan, Hamid Hasson, Gloria Taliani, Antonella D'Arminio Monforte, Claudio Mastroianni, Giovanni Di Perri, Sara Bigoni, Massimo Puoti, Angiola Spinetti, Andrea Gori, Nicola Boffa, Bruno Cacopardo, Andrea Giacometti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Elisabetta Teti, Caterina Pasquazzi, Daniela Segala, Massimo Andreoni

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia-Challenges, strengths, and opportunities in a global health emergency.

    Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia-Challenges, strengths, and opportunities in a global health emergency. by Davide Ferrari, Jovana Milic, Roberto Tonelli, Francesco Ghinelli, Marianna Meschiari, Sara Volpi, Matteo Faltoni, Giacomo Franceschi, Vittorio Iadisernia, Dina Yaacoub, Giacomo Ciusa, Erica Bacca, Carlotta Rogati, Marco Tutone, Giulia Burastero, Alessandro Raimondi, Marianna Menozzi, Erica Franceschini, Gianluca Cuomo, Luca Corradi, Gabriella Orlando, Antonella Santoro, Margherita Digaetano, Cinzia Puzzolante, Federica Carli, Vanni Borghi, Andrea Bedini, Riccardo Fantini, Luca Tabbì, Ivana Castaniere, Stefano Busani, Enrico Clini, Massimo Girardis, Mario Sarti, Andrea Cossarizza, Cristina Mussini, Federica Mandreoli, Paolo Missier, Giovanni Guaraldi

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.

    Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. by Bastian Neesgaard, Amanda Mocroft, Robert Zangerle, Ferdinand Wit, Fiona Lampe, Huldrych F Günthard, Coca Necsoi, Matthew Law, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Christian Pradier, Nikoloz Chkhartisvilli, Juliana Reyes-Uruena, Jörg Janne Vehreschild, Jan-Christian Wasmuth, Anders Sönnerborg, Christoph Stephan, Lauren Greenberg, Josep M Llibre, Alain Volny-Anne, Lars Peters, Annegret Pelchen-Matthews, Vani Vannappagari, Joel Gallant, Armin Rieger, Mike Youle, Dominique Braun, Stephane De Wit, Kathy Petoumenos, Vanni Borghi, Vincenzo Spagnuolo, Tengiz Tsertsvadze, Jens Lundgren, Lene Ryom, RESPOND study group

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: